Top Article: Oral fingolimod (FTY720) in multiple sclerosis. Two-year results of a phase II extension study

Abstract:
Objective: To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS).
Methods: In the randomized, double-blind,… Continue Reading

Case report: A 29-year-old man with rapid onset tetraplegia and respiratory insufficiency

by Svein Ivar Bekkelund
A 29-year-old man with a history of moderate autism and diabetes mellitus treated with insulin presented with a 2-week history of malaise, progressive pareses in both legs and slight weakness in both arms. The last two… Continue Reading